MiMedx Group, Inc. announced on November 14, 2024, that Local Coverage Determinations (LCDs) for skin substitute grafts are set to become effective on February 12, 2025. These revised LCDs will no longer cover over 200 unproven skin substitutes, a significant step towards addressing what MiMedx described as massive reimbursement abuse.
The company's CEO, Joseph H. Capper, applauded the action by Medicare Administrative Contractors (MACs), noting that Medicare spend in this category had escalated to over $1 billion per month. This reform is expected to restore fiscal governance and ensure patient access to clinically proven solutions.
MiMedx is well-positioned to benefit from these changes, as its EPIFIX and EPICORD allografts are explicitly listed among the covered products. The company anticipates gaining market share in an environment that now requires products to demonstrate efficacy with robust clinical evidence.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.